{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06063850",
            "orgStudyIdInfo": {
                "id": "CT-AMT-260-01"
            },
            "organization": {
                "fullName": "UniQure Biopharma B.V.",
                "class": "INDUSTRY"
            },
            "briefTitle": "AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy",
            "officialTitle": "A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "amt-gene-therapy-study-in-adults-with-unilateral-refractory-mesial-temporal-lobe-epilepsy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2023-11-17",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-01",
            "studyFirstSubmitQcDate": "2023-09-25",
            "studyFirstPostDateStruct": {
                "date": "2023-10-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-13",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "uniQure France SAS",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a study of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE). It is designed to investigate the Safety, Tolerability, and Efficacy of AMT-260 in Adults with MTLE Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED).",
            "detailedDescription": "The first-in-human Phase I/IIa U.S. trial consists of two parts. The first part is a multi-center, open-label trial with two dosing cohorts of six patients each to assess safety, tolerability, and first signs of efficacy of AMT-260 in patients with refractory unilateral MTLE. The second part is expected be a randomized, controlled trial to generate proof of concept (POC) data."
        },
        "conditionsModule": {
            "conditions": [
                "Mesial Temporal Lobe Epilepsy"
            ],
            "keywords": [
                "Epilepsy",
                "Temporal Lobe",
                "Hippocampal Sclerosis",
                "Epileptic Syndromes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "maskingDescription": "EEG readers will be blinded",
                    "whoMasked": [
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: AMT-260 starting dose",
                    "type": "EXPERIMENTAL",
                    "description": "N# of treated - 6",
                    "interventionNames": [
                        "Genetic: AAV9-hSyn1-miGRIK2"
                    ]
                },
                {
                    "label": "Cohort 2: AMT-260 adapted dose",
                    "type": "EXPERIMENTAL",
                    "description": "N# of treated - 6\n\nDose is dependent on the DSMB recommendation.",
                    "interventionNames": [
                        "Genetic: AAV9-hSyn1-miGRIK2"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "AAV9-hSyn1-miGRIK2",
                    "description": "AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.",
                    "armGroupLabels": [
                        "Cohort 1: AMT-260 starting dose",
                        "Cohort 2: AMT-260 adapted dose"
                    ],
                    "otherNames": [
                        "AMT-260"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Occurrence of Adverse Events during the period of 1 year after AMT-260 administration, including seriousness, severity, and causal relationship to AMT-260.",
                    "timeFrame": "1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Seizure Frequency",
                    "description": "Change in seizure frequency, comparing baseline to the 1 year period after AMT-260 administration.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Quality of Life in Epilepsy Inventory-31 (QOLIE 31)",
                    "description": "Change from baseline in responses to the QOLIE-31 questionnaire will be assessed on the following subscales; seizure worry, overall quality of life, emotional well-being, energy-fatigue, cognitive function, medication effects, and social functioning.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Patient Health Questionnaire (PHQ9)",
                    "description": "Change from baseline in responses to the PHQ9 will be used to assess the level of depression in participants throughout the study.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "State Trait Anxiety Inventory (STAI)",
                    "description": "Change from baseline in responses to the STAI questionnaire will be used to assess trait anxiety and state anxiety in participants throughout the study.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Pittsburgh Sleep Quality Index (PSQI)",
                    "description": "Change from baseline in responses to the PSQI questionnaire will be assessed on the following components; subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "miRNA in human biofluid (copies/qPCR reaction).",
                    "description": "Stem-loop RT-qPCR analyses will be used to measure miRNA in Cerebrospinal fluid, Blood Serum, Urine, Saliva.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "AAV9 vector in human biofluid (copies/qPCR reaction).",
                    "description": "qPCR analyses will be used to measure AAV9 vector shedding in Cerebrospinal fluid, Blood Serum, Urine, Saliva.",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adult, 18-65 years of age, inclusive, capable of giving informed consent.\n2. Diagnosis of unilateral refractory MTLE for \u2265360 days, confirmed by an Epilepsy Monitoring Unit.\n3. History of seizures with on average \u2265 2 focal onset impaired awareness seizures per 30-day period during the Retrospective Period (3 months prior to screening).\n4. Currently on a stable type and dose regimen of up to a maximum of 4 approved ASDs, for \u22653 months prior to the Retrospective Period.\n5. Confirmed unilateral hippocampal pathology and concordant unilateral seizure focus\n6. Montreal Cognitive Assessment (MoCA) total score \u226526.\n7. No evidence of focal neurocognitive dysfunction, inconsistent with disease pathology- related MRI and (18F)FDG-PET findings.\n8. Women of childbearing potential (WOCBP) and fertile male subjects must be willing and able to use highly effective methods of birth control consistently and correctly throughout the study and for \u2265360 days following AMT-260 administration.\n9. For WOCBP only: Negative pregnancy test.\n\nExclusion Criteria:\n\n1. Implanted devices that would contraindicate MRI; MRI-compatible devices must be implanted \u22653 months prior to Screening (vagus nerve stimulation devices will be up to discretion of the Investigator).\n2. Any other contraindications for generalized anesthesia or surgery.\n3. Medications that could confound clinical (e.g., antipsychotic medication and anti-viral therapy) and laboratory evaluations or could affect a subject's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule.\n4. Any psychogenic nonepileptic seizures within the last year.\n5. Any seizures with contralateral or extra-temporal ictal onset on EEG.\n6. Previous major disease-unrelated neurosurgical intervention due to intracranial tumor, trauma, or bleeding and/or history of previous intracranial surgery for treatment of epileptic seizures.\n7. Magnetic resonance imaging evidence of epileptogenic, extra-temporal lesions, or dual temporal lobe pathology.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Carlien ter Mors",
                    "role": "CONTACT",
                    "phone": "(339) 970-7000",
                    "email": "amt_260_clinical_trials@uniqure.com"
                },
                {
                    "name": "Stephanie Verweij",
                    "role": "CONTACT",
                    "phone": "(339) 970-7000",
                    "email": "amt_260_clinical_trials@uniqure.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Andreas Borta",
                    "affiliation": "uniQure France SAS",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Northeast Regional Epilepsy Group",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hardik Rana",
                            "role": "CONTACT",
                            "phone": "551-497-5000"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Ohio State University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth A Wiley",
                            "role": "CONTACT",
                            "phone": "614-293-3660",
                            "email": "Elizabeth.Wiley@osumc.edu"
                        },
                        {
                            "name": "Dr Singh",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004827",
                    "term": "Epilepsy"
                },
                {
                    "id": "D000004833",
                    "term": "Epilepsy, Temporal Lobe"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000004828",
                    "term": "Epilepsies, Partial"
                },
                {
                    "id": "D000073376",
                    "term": "Epileptic Syndromes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7983",
                    "name": "Epilepsy",
                    "asFound": "Epilepsy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7989",
                    "name": "Epilepsy, Temporal Lobe",
                    "asFound": "Temporal Lobe Epilepsy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2908",
                    "name": "Hippocampal Sclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M1165",
                    "name": "Epileptic Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7984",
                    "name": "Epilepsies, Partial",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                }
            ]
        }
    },
    "hasResults": false
}